Skip to main content

Table 3 Summary of TEAEs

From: Pharmacokinetics and safety of liposomal bupivacaine after local infiltration in healthy Chinese adults: a phase 1 study

Adverse event

Participant, n (%)

Event, n

Any

15 (75)

22

Any TEAE

15 (75)

22

Mild

15 (75)

21

Moderate

1 (5)

1

Any TRAE

1 (5)

1

Mild

1 (5)

1

  1. TEAE treatment-emergent adverse event; TRAE treatment-related adverse event